

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 31 to 38 of 2021**

Statements of Principles Nos. 31 to 38 of 2021 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 26 February 2021. The day of commencement as specified in each of these Instruments is 29 March 2021.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

10 March 2021

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REPEALS** | | | |
|  |  |  |  |
| 31 & 32/2021 | asthma | 29/03/2021 | Nil |
|  |  |  |  |
| 33 & 34/2021 | acute lymphoblastic leukaemia/lymphoblastic lymphoma | 29/03/2021 | Nil |
|  |  |  |  |
| 35 & 36/2021 | deep vein thrombosis | 29/03/2021 | Nil |
|  |  |  |  |
| 37 & 38/2021 | pulmonary thromboembolism | 29/03/2021 | I26 |
|  |  |  |  |

Note:

* The investigation concerning 'acute lymphoblastic leukaemia' has resulted in the determination of Statements of Principles concerning **acute lymphoblastic leukaemia/lymphoblastic lymphoma**.

| **SUMMARY OF CHANGES** | | | |
| --- | --- | --- | --- |
| 31 & 32/2021 | asthma | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *asthma* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 31/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'asthma' in subsection 7(2); * revising the factors in subsections 9(1) and 9(7) concerning being exposed to an immunologic or non-immunologic stimulus, by the inclusion of a note; * revising the factor in subsection 9(2) concerning inhaling very high concentrations of a substance with irritant properties, for clinical onset of reactive airways dysfunction syndrome only, by the inclusion of a note; * revising the factors in subsections 9(3) and 9(8) concerning being overweight or obese; * revising the factors in subsections 9(4) and 9(9) concerning taking a drug from the specified list of drugs; * new factor in subsection 9(5) concerning having smoked tobacco products, for clinical onset; * new factors in subsections 9(6) and 9(11) concerning being exposed to second-hand smoke; * revising the factor in subsection 9(10) concerning having smoked tobacco products, for clinical worsening; * revising the factor in subsection 9(12) concerning having a clinically significant depressive disorder, for clinical worsening only; * revising the factor in subsection 9(13) concerning having gastro-oesophageal disease, for clinical worsening only, by the inclusion of a note; * deleting the factor concerning immersion in an atmosphere with a visible tobacco smoke haze in an enclosed space, for clinical worsening only, as this is now covered by the factors in subsections 9(6) and 9(11) concerning being exposed to second-hand smoke; * new definitions of 'being exposed to second-hand smoke', 'BMI', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being overweight or obese', 'clinical worsening of asthma', 'clinically significant', 'immunologic or non-immunologic stimulus', 'reactive airways dysfunction syndrome' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug or a drug from a class of drugs in the specified list' and 'pack-year of cigarettes, or the equivalent thereof in other tobacco products'.   ***For BoP SoP*** ***(Instrument No. 32/2021)***   * revising the factors in subsections 9(1) and 9(6) concerning being exposed to an immunologic or non-immunologic stimulus, by the inclusion of a note; * revising the factor in subsection 9(2) concerning inhaling very high concentrations of a substance with irritant properties, for clinical onset of reactive airways dysfunction syndrome only, by the inclusion of a note; * revising the factors in subsections 9(3) and 9(7) concerning being overweight or obese; * revising the factors in subsections 9(4) and 9(8) concerning taking a drug from the specified list of drugs; * new factor in subsection 9(5) concerning having smoked tobacco products, for clinical onset; * revising the factor in subsection 9(9) concerning having smoked tobacco products, for clinical worsening; * new factor in subsection 9(10) concerning being exposed to second-hand smoke; * revising the factor in subsection 9(11) concerning having a clinically significant depressive disorder, for clinical worsening only; * revising the factor in subsection 9(12) concerning having gastro-oesophageal disease, for clinical worsening only, by the inclusion of a note; * deleting the factor concerning immersion in an atmosphere with a visible tobacco smoke haze in an enclosed space, for clinical worsening only, as this is now covered by the factor in subsection 9(10) concerning being exposed to second-hand smoke; * new definitions of 'being exposed to second-hand smoke', 'BMI', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being overweight or obese', 'clinical worsening of asthma', 'clinically significant', 'immunologic or non-immunologic stimulus', 'reactive airways dysfunction syndrome' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug or a drug from a class of drugs in the specified list' and 'pack-year of cigarettes, or the equivalent thereof in other tobacco products'.   **The determining of these Instruments finalises the investigation in relation to *asthma* as advertised in the Government Notices Gazette of 29 October 2019.** | |
| 33 & 34/2021 | acute lymphoblastic leukaemia/ lymphoblastic lymphoma | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *acute lymphoblastic leukaemia* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 33/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the name of the condition from 'acute lymphoblastic leukaemia' to 'acute lymphoblastic leukaemia/lymphoblastic lymphoma'; * new definition of 'acute lymphoblastic leukaemia/lymphoblastic lymphoma' in subsection 7(2); * revising the factor in subsection 9(1) concerning having received ionising radiation to the bone marrow, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(2) concerning taking an alkylating agent or a DNA topoisomerase II inhibitor for the treatment of a malignant neoplasm, for clinical onset only; * revising the factor in subsection 9(3) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; * revising the factor in subsection 9(4) concerning being exposed to benzene as specified, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(5) concerning receiving cumulative exposure to benzene, for clinical onset only, by the inclusion of a note; * new definitions of 'MRCA', 'organ or tissue transplantation' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definition of '8-hour time-weighted average (TWA)'.   ***For BoP SoP*** ***(Instrument No. 34/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the name of the condition from 'acute lymphoblastic leukaemia' to 'acute lymphoblastic leukaemia/lymphoblastic lymphoma'; * new definition of 'acute lymphoblastic leukaemia/lymphoblastic lymphoma' in subsection 7(2); * revising the factor in subsection 9(1) concerning having received ionising radiation to the bone marrow, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(2) concerning taking an alkylating agent or a DNA topoisomerase II inhibitor for the treatment of a malignant neoplasm, for clinical onset only; * revising the factor in subsection 9(3) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; * new definitions of 'MRCA', 'organ or tissue transplantation' and 'VEA' in Schedule 1 - Dictionary; and * revising the definition of 'relevant service' in Schedule 1 - Dictionary.   **The determining of these Instruments finalises the investigation in relation to *acute lymphoblastic leukaemia* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 35 & 36/2021 | angle-closure glaucoma | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *deep vein thrombosis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 35/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'deep vein thrombosis' in subsection 7(2); * revising the factor in subsection 9(1) concerning having superficial vein thrombosis, for clinical onset only; * revising the factor in subsection 9(2) concerning having external compression of the affected vein or a vein draining the affected vein, for clinical onset only, by the inclusion of a note; * new factor in subsection 9(3) concerning having an infection involving the affected vein, for clinical onset only; * revising the factor in subsection 9(4) concerning engagement in exercise of the affected upper limb, for clinical onset of deep vein thrombosis in an upper limb only; * revising the factor in subsection 9(5) concerning undergoing a course of therapeutic radiation for cancer, where the affected vein was in the field of radiation, for clinical onset only; * new factor in subsection 9(6) concerning having acute myocardial infarction, for clinical onset only; * new factor in subsection 9(7) concerning having heart failure, for clinical onset only; * revising the factor in subsection 9(10) concerning being overweight or obese, for clinical onset only; * new factor in subsection 9(11) concerning having chronic obstructive pulmonary disease, for clinical onset only; * new factor in subsection 9(12) concerning have sleep apnoea, for clinical onset only; * revising the factor in subsection 9(13) concerning being pregnant, for clinical onset only; * revising the factor in subsection 9(14) concerning having cytomegalovirus infection of new onset, for clinical onset only; * revising the factor in subsection 9(15) concerning having infection with human immunodeficiency virus or hepatitis C virus, for clinical onset only; * new factor in subsection 9(16) concerning having active tuberculosis disease, for clinical onset only; * new factor in subsection 9(17) concerning having coronavirus disease 2019 (COVID-19), for clinical onset only; * revising the factor in subsection 9(18) concerning having an autoimmune disease, for clinical onset only; * new factor in subsection 9(19) concerning having diabetes mellitus, for clinical onset only; * revising the factor in subsection 9(20) concerning having a hypercoagulable state as specified, for clinical onset only; * new factor in subsection 9(21) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * revising the factor in subsection 9(22) concerning having a device implanted within the affected vein, for clinical onset only; * revising the factor in subsection 9(24) concerning having an injury or illness as specified, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(25) concerning having restricted mobility, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(26) concerning having a neurological disease that causes loss or impairment of motor function of a limb, for clinical onset only; * new factor in subsection 9(27) concerning having a clinically significant disorder of mental health as specified, for clinical onset only; * revising the factor in subsection 9(28) concerning taking a drug from the specified list of drugs, for clinical onset only; * revising the factor in subsection 9(29) concerning taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for clinical onset only; * new factor in subsection 9(30) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * new factor in subsection 9(31) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * revising the factor in subsection 9(32) concerning being at an altitude of at least 3,000 metres, for clinical onset only; * deleting the factor concerning having osteomyelitis, an abscess or other infection involving the affected vein, for clinical onset only, as this is now covered by the factor in subsection 9(3) concerning having an infection involving the affected vein, for clinical onset only; * deleting the factor concerning having a cardiac disease from the specified list, for clinical onset only, as this is now covered by the factors in: * subsection 9(6) concerning having acute myocardial infarction, for clinical onset only; * subsection 9(7) concerning having heart failure, for clinical onset only; * deleting the factor concerning having chronic bronchitis or emphysema, for clinical onset only, as this is now covered by the factor in subsection 9(11) concerning having chronic obstructive pulmonary disease, for clinical onset only; * deleting the factor concerning experiencing animal envenomation from the bite of a viper, *Crotalinae* spp or *Bitis gabonica*, for clinical onset only, as this is now covered by the factor in subsection 9(20) concerning having a hypercoagulable state as specified, for clinical onset only; * deleting the factor concerning having nephrotic syndrome, or any acute or chronic renal disease requiring dialysis or renal transplant, for clinical onset only, as this is now covered by the factor in subsection 9(21) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * deleting the factor concerning immobilisation of the affected upper or lower limb in a plaster cast or similar restraining or bracing device, for clinical onset only, as this is now covered by the factor in subsection 9(24) concerning having an injury or illness as specified, for clinical onset only; * deleting the factor concerning having depressive disorder with severe psychomotor retardation, for clinical onset only, as this is now covered by the factor in subsection 9(27) concerning having a clinically significant disorder of mental health as specified, for clinical onset only; * deleting the factor concerning smoking of cigarettes or other tobacco products, for clinical onset only, as this is now covered by the factors in: * subsection 9(30) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * subsection 9(31) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * deleting the factor concerning having trauma to the affected vein, for clinical onset only; * deleting the factor concerning being an inpatient in a hospital or a resident in a nursing home, for clinical onset only; * new definitions of 'abnormality of kidney structure or function', 'active tuberculosis disease', 'acute kidney injury', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'cigarettes per day, or the equivalent thereof in other tobacco products', 'clinically significant disorder of mental health as specified', 'hypercoagulable state as specified', 'menopausal hormone therapy', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs', 'specified list of kidney diseases', 'traumatic upper or lower limb amputation' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'exercise of the affected upper limb', 'external compression of the affected vein or a vein draining the affected vein', 'injury or illness as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a cardiac disease from the specified list', 'a drug or a drug from a class of drugs from the specified list', 'a hypercoagulable state', 'an autoimmune disease or inflammatory vasculitis from the specified list', 'a neurological disease causing motor impairment', 'being obese', 'having restricted mobility', 'hormone replacement therapy', 'pack-year of cigarettes, or the equivalent thereof in other tobacco products', 'psychomotor retardation' and 'trauma to the affected vein'.   ***For BoP SoP*** ***(Instrument No. 36/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'deep vein thrombosis' in subsection 7(2); * revising the factor in subsection 9(1) concerning having superficial vein thrombosis, for clinical onset only; * revising the factor in subsection 9(2) concerning having external compression of the affected vein or a vein draining the affected vein, for clinical onset only, by the inclusion of a note; * new factor in subsection 9(3) concerning having an infection involving the affected vein, for clinical onset only; * revising the factor in subsection 9(4) concerning engagement in exercise of the affected upper limb, for clinical onset of deep vein thrombosis in an upper limb only; * new factor in subsection 9(5) concerning having acute myocardial infarction, for clinical onset only; * new factor in subsection 9(6) concerning having heart failure, for clinical onset only; * revising the factor in subsection 9(9) concerning being overweight or obese, for clinical onset only; * new factor in subsection 9(10) concerning having sleep apnoea, for clinical onset only; * revising the factor in subsection 9(11) concerning being pregnant, for clinical onset only; * revising the factor in subsection 9(12) concerning having infection with human immunodeficiency virus or hepatitis C virus, for clinical onset only; * new factor in subsection 9(13) concerning having coronavirus disease 2019 (COVID-19), for clinical onset only; * revising the factor in subsection 9(14) concerning having an autoimmune disease, for clinical onset only; * new factor in subsection 9(15) concerning having diabetes mellitus, for clinical onset only; * revising the factor in subsection 9(16) concerning having a hypercoagulable state as specified, for clinical onset only; * new factor in subsection 9(17) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * revising the factor in subsection 9(18) concerning having a device implanted within the affected vein, for clinical onset only; * revising the factor in subsection 9(19) concerning having surgery requiring a general, spinal or epidural anaesthetic, for clinical onset only; * revising the factor in subsection 9(20) concerning having an injury or illness as specified, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(21) concerning having restricted mobility, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(22) concerning having a neurological disease that causes loss or impairment of motor function of a limb, for clinical onset only; * revising the factor in subsection 9(23) concerning taking a drug from the specified list of drugs; * revising the factor in subsection 9(24) concerning taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for clinical onset only; * new factor in subsection 9(25) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * new factor in subsection 9(26) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * new factor in subsection 9(27) concerning being at an altitude of at least 3,000 metres, for clinical onset only; * deleting the factor concerning having osteomyelitis, an abscess or other infection involving the affected vein, for clinical onset only, as this is now covered by the factor in subsection 9(3) concerning having an infection involving the affected vein, for clinical onset only; * deleting the factor concerning having a cardiac disease from the specified list, for clinical onset only, as this is now covered by the factors in: * subsection 9(5) concerning having acute myocardial infarction, for clinical onset only; * subsection 9(6) concerning having heart failure, for clinical onset only; * deleting the factor concerning experiencing animal envenomation from the bite of a viper, *Crotalinae* spp or *Bitis gabonica*, for clinical onset only, as this is now covered by the factor in subsection 9(16) concerning having a hypercoagulable state as specified, for clinical onset only; * deleting the factor concerning having nephrotic syndrome, or any acute or chronic renal disease requiring dialysis or renal transplant, for clinical onset only, as this is now covered by the factor in subsection 9(17) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * deleting the factor concerning immobilisation of the affected upper or lower limb in a plaster cast or similar restraining or bracing device, for clinical onset only, as this is now covered by the factor in subsection 9(20) concerning having an injury or illness as specified, for clinical onset only; * deleting the factor concerning smoking of cigarettes or other tobacco products, for clinical onset only, as this is now covered by the factors in: * subsection 9(25) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * subsection 9(26) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * deleting the factor concerning having trauma to the affected vein, for clinical onset only; * deleting the factor concerning undergoing a course of therapeutic radiation, where the affected vein was in the field of radiation, for clinical onset only; * deleting the factor concerning having chronic bronchitis or emphysema, for clinical onset only; * deleting the factor concerning having cytomegalovirus infection of new onset, for clinical onset only; * deleting the factor concerning being an inpatient in a hospital or a resident in a nursing home, for clinical onset only; * new definitions of 'abnormality of kidney structure or function', 'acute kidney injury', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'cigarettes per day, or the equivalent thereof in other tobacco products', 'hypercoagulable state as specified', 'menopausal hormone therapy', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs', 'specified list of kidney diseases', 'traumatic upper or lower limb amputation' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'exercise of the affected upper limb', 'external compression of the affected vein or a vein draining the affected vein', 'injury or illness as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a cardiac disease from the specified list', 'a drug or a drug from a class of drugs from the specified list', 'a hypercoagulable state', 'an autoimmune disease or inflammatory vasculitis from the specified list', 'a neurological disease causing motor impairment', 'being obese', 'having restricted mobility', 'hormone replacement therapy', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'trauma to the affected vein'.   On 2 November 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to *having trauma to the affected vein within the six months before the clinical onset of deep vein thrombosis* and *being an inpatient in a hospital or a resident in a nursing home for a continuous period of at least seven days, within the six months before the clinical onset of deep vein thrombosis* from the reasonable hypothesis Statement of Principles and the deletion of factors relating to *having trauma to the affected vein within the three months before the clinical onset of deep vein thrombosis, undergoing a course of therapeutic radiation, where the affected vein was in the field of radiation, within the three months before the clinical onset of deep vein thrombosis, being an inpatient in a hospital or a resident in a nursing home for a continuous period of at least seven days, within the three months before the clinical onset of deep vein thrombosis, having cytomegalovirus infection of new onset within the six weeks before the clinical onset of deep vein thrombosis* and *having chronic bronchitis or emphysema at the time of the clinical onset of deep vein thrombosis* from the balance of probabilities Statement of Principles. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instrument following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *deep vein thrombosis* as advertised in the Government Notices Gazette of 29 October 2019.** |
| 37 & 38/2021 | pulmonary thromboembolism | | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning *pulmonary thromboembolism* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 37/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(2) concerning having superficial vein thrombosis, for clinical onset only; * new factor in subsection 9(3) concerning having acute myocardial infarction, for clinical onset only; * new factor in subsection 9(4) concerning having heart failure or a thrombus within the right atrium or right ventricle, for clinical onset only; * revising the factor in subsection 9(7) concerning being overweight or obese, for clinical onset only; * new factor in subsection 9(8) concerning having chronic obstructive pulmonary disease, for clinical onset only; * new factor in subsection 9(9) concerning having sleep apnoea, for clinical onset only; * revising the factor in subsection 9(10) concerning being pregnant, for clinical onset only; * revising the factor in subsection 9(11) concerning having cytomegalovirus, for clinical onset only; * revising the factor in subsection 9(12) concerning having infection with human immunodeficiency virus or hepatitis C virus, for clinical onset only; * new factor in subsection 9(13) concerning having active tuberculosis disease, for clinical onset only; * new factor in subsection 9(14) concerning having coronavirus disease 2019 (COVID-19), for clinical onset only; * revising the factor in subsection 9(15) concerning having an autoimmune disease, for clinical onset only; * new factor in subsection 9(16) concerning having diabetes mellitus, for clinical onset only; * revising the factor in subsection 9(17) concerning having a hypercoagulable state as specified, for clinical onset only; * new factor in subsection 9(18) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * revising the factor in subsection 9(19) concerning having implantation of an intravenous device, for clinical onset only; * revising the factor in subsection 9(21) concerning having an injury or illness as specified, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(22) concerning having restricted mobility for a continuous period, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(23) concerning having a neurological disease that causes loss or impairment of motor function of a limb, for clinical onset only; * new factor in subsection 9(24) concerning having a clinically significant disorder of mental health, for clinical onset only; * revising the factor in subsection 9(25) concerning taking a drug from the specified list of drugs, for clinical onset only; * revising the factor in subsection 9(26) concerning taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for clinical onset only; * new factor in subsection 9(27) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * new factor in subsection 9(28) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * revising the factor in subsection 9(29) concerning being at an altitude of at least 3,000 metres, for clinical onset only; * deleting the factor concerning having a cardiac disease from the specified list, for clinical onset only, as this is now covered by the factors in: * subsection 9(3) concerning having acute myocardial infarction, for clinical onset only; * subsection 9(4) concerning having heart failure or a thrombus within the right atrium or right ventricle, for clinical onset only; * deleting the factor concerning having chronic bronchitis or emphysema, for clinical onset only, as this is now covered by the factor in subsection 9(8) concerning having chronic obstructive pulmonary disease, for clinical onset only; * deleting the factor concerning experiencing animal envenomation from the bite of a viper, *Crotalinae* spp or *Bitis gabonica*, for clinical onset only, as this is now covered by the factor in subsection 9(17) concerning having a hypercoagulable state as specified, for clinical onset only; * deleting the factor concerning having nephrotic syndrome, or any acute or chronic renal disease requiring dialysis or renal transplantation, for clinical onset only, as this is now covered by the factor in subsection 9(18) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * deleting the factor concerning immobilisation of the upper or lower limb in a plaster cast or similar restraining device, for clinical onset only, as this is now covered by the factor in subsection 9(21) concerning having an injury or illness as specified, for clinical onset only; * deleting the factor concerning having depressive disorder with severe psychomotor retardation, for clinical onset only, as this is now covered by the factor in subsection 9(24) concerning having a clinically significant disorder of mental health, for clinical onset only; * deleting the factor concerning smoking of cigarettes or tobacco products, for clinical onset only, as this is now covered by the factors in: * subsection 9(27) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * subsection 9(28) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * deleting the factor concerning being an inpatient in a hospital or a resident in a nursing home, for clinical onset only; * new definitions of 'abnormality of kidney structure or function', 'active tuberculosis disease', 'acute kidney injury', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'cigarettes per day, or the equivalent thereof in other tobacco products', 'clinically significant disorder of mental health', 'hypercoagulable state as specified', 'menopausal hormone therapy', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs', 'specified list of kidney diseases', 'traumatic upper or lower limb amputation' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'injury or illness as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a cardiac disease from the specified list', 'a drug or a drug from a class of drugs from the specified list', 'a hypercoagulable state', 'an autoimmune disease or inflammatory vasculitis from the specified list', 'a neurological disease causing motor impairment', 'being obese', 'having restricted mobility', 'hormone replacement therapy', 'pack-year of cigarettes, or the equivalent thereof in other tobacco products', 'psychomotor retardation' and 'venous thrombosis'.   ***For BoP SoP*** ***(Instrument No. 38/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(2) concerning having superficial vein thrombosis, for clinical onset only; * new factor in subsection 9(3) concerning having acute myocardial infarction, for clinical onset only; * new factor in subsection 9(4) concerning having heart failure or a thrombus within the right atrium or right ventricle, for clinical onset only; * revising the factor in subsection 9(7) concerning being overweight or obese, for clinical onset only; * new factor in subsection 9(8) concerning having sleep apnoea, for clinical onset only; * revising the factor in subsection 9(9) concerning being pregnant, for clinical onset only; * revising the factor in subsection 9(10) concerning having infection with human immunodeficiency virus, for clinical onset only; * new factor in subsection 9(11) concerning having coronavirus disease 2019 (COVID-19), for clinical onset only; * revising the factor in subsection 9(12) concerning having an autoimmune disease, for clinical onset only; * new factor in subsection 9(13) concerning having diabetes mellitus, for clinical onset only; * revising the factor in subsection 9(14) concerning having a hypercoagulable state as specified, for clinical onset only; * new factor in subsection 9(15) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * revising the factor in subsection 9(16) concerning having implantation of an intravenous device, for clinical onset only; * revising the factor in subsection 9(17) concerning having surgery requiring a general, spinal or epidural anaesthetic, for clinical onset only; * revising the factor in subsection 9(18) concerning having an injury or illness as specified, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(19) concerning having restricted mobility, for clinical onset only, by the inclusion of a note; * revising the factor in subsection 9(20) concerning having a neurological disease that causes loss or impairment of motor function of a limb, for clinical onset only; * revising the factor in subsection 9(21) concerning taking a drug from the specified list of drugs, for clinical onset only; * revising the factor in subsection 9(22) concerning taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for clinical onset only; * new factor in subsection 9(23) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * new factor in subsection 9(24) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * revising the factor in subsection 9(25) concerning being at an altitude of at least 3,000 metres, for clinical onset only; * deleting the factor concerning having a cardiac disease from the specified list, for clinical onset only, as this is now covered by the factors in: * subsection 9(3) concerning having acute myocardial infarction, for clinical onset only; * subsection 9(4) concerning having heart failure or a thrombus within the right atrium or right ventricle, for clinical onset only; * deleting the factor concerning experiencing animal envenomation from the bite of a viper, *Crotalinae* spp or *Bitis gabonica*, for clinical onset only, as this now covered by the factor in subsection 9(14) concerning having a hypercoagulable state as specified, for clinical onset only; * deleting the factor concerning having nephrotic syndrome, or any acute or chronic renal disease requiring dialysis or renal transplantation, for clinical onset only, as this is now covered by the factor in subsection 9(15) concerning having a kidney disease from the specified list of kidney diseases, for clinical onset only; * deleting the factor concerning immobilisation of the upper or lower limb in a plaster cast or similar restraining device, as this is now covered by the factor in subsection 9(18) concerning having an injury or illness as specified, for clinical onset only; * deleting the factor concerning smoking of cigarettes or tobacco products, for clinical onset only, as this is now covered by the factors in: * subsection 9(23) concerning having smoked tobacco products or cigarettes, where smoking has not permanently ceased, for clinical onset only; * subsection 9(24) concerning having smoked tobacco products or cigarettes, where smoking has permanently ceased, for clinical onset only; * deleting the factor concerning having chronic bronchitis or emphysema, for clinical onset only; * deleting the factor concerning having cytomegalovirus infection of new onset, for clinical onset only; * deleting the factor concerning being an inpatient in a hospital or a resident in a nursing home, for clinical onset only; * new definitions of 'abnormality of kidney structure or function', 'acute kidney injury', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'cigarettes per day, or the equivalent thereof in other tobacco products', 'hypercoagulable state as specified', 'menopausal hormone therapy', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs', 'specified list of kidney diseases', 'traumatic upper or lower limb amputation' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'injury or illness as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a cardiac disease from the specified list', 'a drug or a drug from a class of drugs from the specified list', 'a hypercoagulable state', 'an autoimmune disease or inflammatory vasculitis from the specified list', 'a neurological disease causing motor impairment', 'being obese', 'having restricted mobility', 'hormone replacement therapy', 'pack-year of cigarettes, or the equivalent thereof in other tobacco products' and 'venous thrombosis'.   On 2 November 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factor relating to *being an inpatient in a hospital or a resident in a nursing home for a continuous period of at least seven days, within the six months before the clinical onset of pulmonary thromboembolism* from the reasonable hypothesis Statement of Principles and the deletion of factors relating to *being an inpatient in a hospital or a resident in a nursing home for a continuous period of at least seven days, within the three months before the clinical onset of pulmonary thromboembolism, having cytomegalovirus infection of new onset within the six weeks before the clinical onset of pulmonary thromboembolism* and *having chronic bronchitis or emphysema at the time of the clinical onset of pulmonary thromboembolism* from the balance of probabilities Statement of Principles. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instrument following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *chronic pulmonary thromboembolism* as advertised in the Government Notices Gazette of 29 October 2019.** |